Open AccessMHC‐Ig induces memory T cell formation in vivo and inhibits tumour growth
Author(s) -
Schütz Christian,
Zoso Alessia,
Peng Shiwen,
Bennett Jonathon D.,
Schneck Jonathan P.,
Oelke Mathias
Publication year - 2014
Publication title -
immunity, inflammation and disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 18
ISSN - 2050-4527
DOI - 10.1002/iid3.35
Subject(s) - major histocompatibility complex , antigen , biology , t cell , immune system , cytotoxic t cell , antigen presenting cell , in vivo , microbiology and biotechnology , immunology , in vitro , biochemistry
Abstract Induction of a T cell mediated immune response is critical for the eradication of viral infections and tumours. Soluble peptide‐loaded major histocompatibility complex‐Ig ( pep− MHC‐Ig) have been shown to bind their cognate ligands, T cell receptor, with high affinity, and are successfully used to visualize antigen‐specific T cells. Furthermore, immobilized pep− MHC‐Ig can activate and expand antigen‐specific T cells in vitro and in vivo . In this study, we investigate the use of pep− MHC‐Ig as a potential strategy to modulate antigen specific T cell immune responses in vivo . SIY− K b ‐Ig immunization, together with the pre‐activation by an anti‐CD40 monoclonal antibody, is able to stimulate a strong expansion of adoptively transferred 2C transgenic T cells and the formation of long term antigen‐specific memory T cells. In addition, mechanistic studies show that the pep− MHC‐Ig molecules directly activate T cells in vivo without requiring uptake and reprocessing by antigen‐presenting cells. Furthermore, B6 mice immunized with pep− MHC‐Ig molecules inhibit tumour growth in a B16‐SIY melanoma prevention model. Thus, soluble pep− MHC‐Ig molecules represent a powerful tool for active immunotherapy.